SRI-31277

Overview

SRI-31277 is a thrombospondin 1 (TSP-1) inhibitor with a human target pIC 50 of 8.28 nM and in vivo activity, and exhibits a very short plasma half-life with intravenous administration.SRI-31277 inhibits interaction between TSP-1 and the latency-associated peptide (LAP) of latent TGF-β , blocking TSP-1-mediated TGF-β activation.SRI-31277 can be used for the research of multiple myeloma and fibrotic conditions.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Multiple Myeloma | Products > Signaling Pathways > TGF-beta/Smad | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > TGF-β Receptor

Product Information

• Catalog No.: HY-182611
• CAS No.: 1637468-93-9
• Molecular Formula: C17H33N5O5
• Molecular Weight: 387.47
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source